Format

Send to

Choose Destination
Antiviral Res. 2018 Feb;150:183-192. doi: 10.1016/j.antiviral.2017.12.022. Epub 2018 Jan 2.

Filovirus proteins for antiviral drug discovery: Structure/function of proteins involved in assembly and budding.

Author information

1
Laboratoire Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR7257 CNRS, Parc Scientifique de Luminy, Aix-Marseille Université, Marseille, France.
2
Molecular Basis of Viral Pathogenicity, International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, Université Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France.
3
Molecular Basis of Viral Pathogenicity, International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, Université Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France. Electronic address: viktor.volchkov@inserm.fr.
4
Laboratoire Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR7257 CNRS, Parc Scientifique de Luminy, Aix-Marseille Université, Marseille, France. Electronic address: etienne.decroly@afmb.univ-mrs.fr.

Abstract

There are no approved medications for the treatment of Marburg or Ebola virus infection. In two previous articles (Martin et al., 2016, Martin et al., 2017), we reviewed surface glycoprotein and replication proteins structure/function relationship to decipher the molecular mechanisms of filovirus life cycle and identify antiviral strategies. In the present article, we recapitulate knowledge about the viral proteins involved in filovirus assembly and budding. First we describe the structural data available for viral proteins associated with virus assembly and virion egress and then, we integrate the structural features of these proteins in the functional context of the viral replication cycle. Finally, we summarize recent advances in the development of innovative antiviral strategies to target filovirus assembly and egress. The development of such prophylactic or post-exposure treatments could help controlling future filovirus outbreaks.

KEYWORDS:

Antiviral therapy; Ebola virus; Filovirus; Marburg virus; Mononegavirales; Virion assembly

PMID:
29305306
DOI:
10.1016/j.antiviral.2017.12.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center